Core Viewpoint - The "climax needle" concept stock experienced extreme volatility in the market, revealing the dark side of the medical beauty industry and the collusion between capital and human greed [2][3]. Group 1: Medical Device Misrepresentation - The "climax needle" is based on a medical device originally intended for orthopedic use, specifically a PRP preparation device, which was misrepresented in marketing as a vaginal injection for enhancing sexual pleasure [2][4]. - The approval process for PRP devices is stringent, requiring an average of 5.2 years for clinical trials and registration, yet significant regulatory loopholes exist [4]. Group 2: Market Reactions and Financial Implications - The stock of Bawei Co. surged by 2.3 billion yuan on April 26, only to plummet by 9% the next day, indicating a rapid shift from market enthusiasm to panic [3]. - The medical beauty sector's sales of PRP products reached over 1.4 billion yuan in 2023, highlighting the financial scale of the misrepresentation [5]. Group 3: Consumer Impact and Regulatory Response - Numerous cases of severe complications from the "climax needle" have been reported, including infections and permanent damage, underscoring the risks to consumers [7][12]. - Regulatory bodies are taking action, including the launch of a "medical beauty device cleansing action" and the implementation of a black-and-white list system for medical institutions [12]. Group 4: Proposed Solutions - Recommendations for addressing the issues include implementing traceability for medical devices, establishing ethical review committees for medical beauty technologies, and allowing collective lawsuits for consumers [9][10][11].

Core Viewpoint - The "climax needle" concept has led to significant stock price fluctuations in related companies, highlighting the volatility and speculative nature of the medical beauty industry [1][4]. Group 1: Market Reaction - On April 28, after the opening of A-shares, stocks related to the "climax needle" concept experienced a collective decline, with Bawei Co. (837023) dropping over 9%, Demei Chemical (002054.SZ) down more than 7%, and Tianyuan Co. (002386.SZ) falling over 5% [1]. - Prior to the decline, these stocks had surged due to speculation surrounding the "climax needle," with some reaching their daily limit [1]. Group 2: Product Details - The "climax needle" is marketed as an injection of collagen at sensitive points within the female vagina, with prices ranging from thousands to tens of thousands of yuan [1]. - A specific product developed by Yuanxiang Biotechnology is priced at 9,800 yuan per injection and is classified as a "platelet-rich plasma preparation device" (PRP), which is a strictly regulated Class III medical device [3]. Group 3: Medical and Regulatory Insights - PRP technology involves extracting a patient's blood, processing it to concentrate platelets, and utilizing growth factors for tissue repair and regeneration [3]. - While PRP has been increasingly applied in the medical beauty sector, the National Medical Products Administration has not yet issued clear approvals for its use in facial injections, despite existing clinical literature [3][4]. - Experts have criticized the "climax needle" as lacking scientific support and warned of potential risks associated with its use, indicating a need for regulatory scrutiny in the medical beauty industry [1][4].